REQUEST A DEMO
Total
USD $0.00
Search more companies

Green-Swan Pharmaceuticals Cr A.S. (Czech Republic)

Main Activities: All Other Miscellaneous Food Manufacturing
Full name: Green-Swan Pharmaceuticals Cr A.S. Profile Updated: January 02, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2021 Available in: English Download a sample report

Green-Swan Pharmaceuticals Cr A.S. is based in Czech Republic, with the head office in Prague. It operates in the All Other Miscellaneous Food Manufacturing sector. The enterprise was incorporated on December 31, 2017. It currently has a total number of 25 - 49 (2023) employees. The latest financial highlights indicate a net sales revenue increase of 6.52% in 2021. Over the same period, its total assets grew by 16.93%. The net profit margin of Green-Swan Pharmaceuticals Cr A.S. decreased by 4.18% in 2021.

Headquarters
Chodov, Tomickova 2144/1
Prague; The City of Prague; Postal Code: 14800

Contact Details: Purchase the Green-Swan Pharmaceuticals Cr A.S. report to view the information.

Basic Information
Total Employees:
Purchase the Green-Swan Pharmaceuticals Cr A.S. report to view the information.
Outstanding Shares:
Purchase the Green-Swan Pharmaceuticals Cr A.S. report to view the information.
Incorporation Date:
December 31, 2017
Key Executives
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Supervisory Board
Company Performance
Financial values in the chart are available after Green-Swan Pharmaceuticals Cr A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
6.52%
Total operating revenue
7.05%
Operating profit (EBIT)
-16.28%
EBITDA
-16.3%
Net Profit (Loss) for the Period
-23.32%
Total assets
16.93%
Total equity
27.03%
Operating Profit Margin (ROS)
-3.82%
Net Profit Margin
-4.18%
Return on Equity (ROE)
-14.7%
Quick Ratio
0.02%
Cash Ratio
0.08%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?